share_log

4: Statement of changes in beneficial ownership of securities-Director Lewis-Hall Freda C

4: Statement of changes in beneficial ownership of securities-Director Lewis-Hall Freda C

4:持股变动声明-董事 Lewis-Hall Freda C
美股SEC公告 ·  2024/12/20 17:10

Moomoo AI 已提取核心信息

Freda C Lewis-Hall, associated with Conduit Pharmaceuticals, has reported an upcoming transaction scheduled for December 18, 2024. The nature and details of this transaction have not been disclosed in the current filing.The reporting person's address is listed as 4851 Tamiami Trail North, Suite 200, Naples, FL, 34103. While the filing indicates a future event, it does not specify the type of securities involved or the quantity to be transacted. The relationship between Lewis-Hall and the issuer has not been explicitly stated in this announcement.
Freda C Lewis-Hall, associated with Conduit Pharmaceuticals, has reported an upcoming transaction scheduled for December 18, 2024. The nature and details of this transaction have not been disclosed in the current filing.The reporting person's address is listed as 4851 Tamiami Trail North, Suite 200, Naples, FL, 34103. While the filing indicates a future event, it does not specify the type of securities involved or the quantity to be transacted. The relationship between Lewis-Hall and the issuer has not been explicitly stated in this announcement.
Freda C Lewis-Hall与Conduit Pharmaceuticals有关,已报告一项计划于2024年12月18日进行的交易。该交易的性质和细节在当前的申报中尚未披露。报告人的地址列为4851 Tamiami Trail North, Suite 200, Naples, FL, 34103。虽然申报中指明了一个未来事件,但并没有具体说明所涉及的证券类型或交易数量。Lewis-Hall与发行人之间的关系在此公告中没有明确说明。
Freda C Lewis-Hall与Conduit Pharmaceuticals有关,已报告一项计划于2024年12月18日进行的交易。该交易的性质和细节在当前的申报中尚未披露。报告人的地址列为4851 Tamiami Trail North, Suite 200, Naples, FL, 34103。虽然申报中指明了一个未来事件,但并没有具体说明所涉及的证券类型或交易数量。Lewis-Hall与发行人之间的关系在此公告中没有明确说明。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息